<< Back to News

System Formulary Update
HIV Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)

Situation

The NNRTI class review and formulary standardization was approved at the October 2020 System Pharmacy and Therapeutics Committee meeting.

Background

The following medications were reviewed: doravirine, efavirenz, etravirine, nevirapine, rilpivirine, and combinations of the aforementioned agents.

Assessment/Recommendations

Changes Effective: Tuesday, February 23, 2021

System P&T voted to include the following products on the UNC Health System Drug Formulary:

• Efavirenz tablet: 600 mg
• Etravirine tablet: 200 mg
• Nevirapine oral suspension: 50 mg/5 mL (240 mL bottle)
• Rilpivirine tablet: 25 mg

Note: Stock of these formulary products may vary at individual entities

As a result, the following products will be removed from the inpatient drug formulary:

• Doravirine tablet: 100 mg
• Doravirine/lamivudine/TDF (Delstrigo): 100 mg/300 mg/300 mg
• Efavirenz capsule: 50 mg, 200 mg
• Efavirenz/emtricitabine/TDF (Atripla): 600 mg/200 mg/300 mg
• Efavirenz/lamivudine/TDF (Symfi): 400 mg/300 mg/300 mg, 600 mg/300 mg/300 mg
• Etravirine tablet: 25 mg, 50 mg, 100 mg
• Nevirapine IR tablet: 200 mg
• Nevirapine ER tablet: 400 mg
• Nevirapine/lamivudine/stavudine (Triomune): 150 mg/15 mg/200 mg
• Rilpivirine/emtricitabine/TDF (Complera): 25 mg/200 mg/300 mg
• Rilpivirine/emtricitabine/TAF (Odefsey): 25 mg/200 mg/26 mg
• Dolutegravir/rilpivirine (Juluca): 50 mg/25 mg